Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ,x]xtg?
N5%Cwl6i
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 24; BY'
YB?5s`vr9d
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© muZ6 }&4
-V\$oVS0S
1.Co-stimulators (or co-stimulating molecules) cZFG~n/
^:Hx .
2.NK-kB gOSFvH8FU
r,FPTf
3.Immunoglobulin superfamily &X`zk
,+mH1#-3
4.antigen-presenting cell (APC) =TcT` ](o
#J_+
SL[
5.death domain BnwYyh
+yO^,{8SE
6.CCR and CXCR 4eh~/o&h
Q}qw`L1
7.Lectin (or mitogen) piPx8jT`F
.9'bi#:Cw
8.Clusters of differentiation, CD) {<J(*K*\Jo
uNoP8U%*
9.B7 family A-GU:B
~;ZT<eCIA
10.Cytotoxic T lymphocyte, CTL) =e j'5m($3
Zy+EI
x
11.IL-15 and IL-15 receptor (IL-15R) ]\ DIJ>JZ
P"k`h=>!4
12.MHC restriction '}pe$=
YuVg/ '=
13.Affinity-chromatography ?K9zTas@
[e.@Yx_}
14.Cyctosprin A, CsA ?K>=>bS^h
?]In@h-
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) </@3}rfUPg
vOnhJN
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 1.6Y=Mh=i[
?x-:JME0
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Fmo^ ?~b
eJ2$DgB}t
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ckCb)r_
[:xpz,
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ >?yxig:_
/~nPPC
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© +GDT@,/
|o0?u:
ÃâÒßѧרҵ£º <
X&{6xu
L,PD4H"8
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ KBSO^<7
530Z>
q
Ïû»¯ÄÚ¿Æ£º *!p#1fE
4y$tp18
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /QT"5fxKJ
/ltGSl
ѪҺ²¡Ñ§×¨Òµ£º WK)2/$7@
),53(=/hl
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿